Overview
Overview
Featured Story
Medical Affairs: the navigator of pharma’s new world order
PharmaTimes Online | July 2018
The most important role in the emerging future of the pharmaceutical industry is medical affairs – a responsibility long viewed as a support function.
Read more ›Overview
News
Pharma’s Digital Awakening: Research-Ready Health Information And AI To Reduce Cost And Deliver Better Treatments
Clinical Leader | August 2019
Using real-world data to represent the evolving demands and requirements of targeted markets—as demonstrated in the automotive industry—would create drug manufacturing pipelines that are living ecosystems, ushering flexible production into the pharmaceutical industry.
Read more ›
News
Differentiating Oncology Research Pipeline In Today’s Competitive Era
Clinical Leader | August 2019
Big pharma is increasingly doubling down on bets to develop new blockbuster cancer drugs. Currently, approximately 700 organizations have one or more oncology drugs in late-stage development, and 14 of the world’s largest pharmaceutical companies are focusing at least one-third of their late-stage R&D activity on oncology.
Read more ›
News
Real-World Evidence: Explaining The Current State Of The FDA’s RWE Program
Clinical Leader | February 25, 2019
This article will guide you through the program and what it means for drug developers and explain the potential that real-world data (RWD) offers in developing RWE to significantly and safely accelerate the drug approval process.
Read more ›